Inhaled bronchodilators and acute myocardial infarction: a nested case-control study.

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• Respiratory Medicine

Background:

• Inhaled bronchodilators are widely used for respiratory conditions.
• Understanding their cardiovascular safety profile is crucial for patient management.
• Previous studies have yielded conflicting results regarding the association between bronchodilator use and acute myocardial infarction (AMI).

Purpose of the Study:

• To investigate the association between different types of inhaled bronchodilators and the risk of AMI.
• To evaluate the impact of specific inhaler device types (DPI vs. SMI) on AMI risk.
• To examine these associations in patient subgroups, including those with hypertension or diabetes, and concomitant beta-blocker use.

Main Methods:

• A nested case-control study design was employed.
• Data were sourced from a nationwide insurance claims database.
• 11,054 AMI cases and 47,815 matched controls were identified from over 1 million subjects.

Main Results:

• Long-acting and short-acting beta-agonists (LABAs/SABAs) were associated with an increased risk of AMI.
• LABAs combined with inhaled corticosteroids (ICSs) did not show an increased AMI risk.
• Long-acting muscarinic antagonists (LAMAs) delivered via dry powder inhaler (DPI) were associated with a reduced AMI risk, whereas LAMAs in soft mist inhalers (SMIs) did not show this protective effect.
• In patients with hypertension or diabetes, LAMAs in DPIs were linked to reduced AMI risk, while LABAs showed an increased risk.
• The risk reduction associated with LAMAs was most significant among beta-blocker users.

Conclusions:

• Inhaled beta-agonists (LABAs/SABAs) are associated with an increased risk of AMI.
• The combination of LABAs with ICSs mitigates this increased risk.
• LAMAs delivered via DPI are associated with a lower risk of AMI, particularly in specific patient populations and when used concurrently with beta-blockers.